We are live on ! Find out more
EXAS

Exact Sciences

Delisted

EXAS was delisted on the 20th of March, 2026.

646 hedge funds and large institutions have $20.2B invested in Exact Sciences in 2021 Q1 according to their latest regulatory filings, with 99 funds opening new positions, 263 increasing their positions, 180 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more repeat investments, than reductions

Existing positions increased: 263 | Existing positions reduced: 180

46% more first-time investments, than exits

New positions opened: 99 | Existing positions closed: 68

4% more funds holding

Funds holding: 622646 (+24)

4% more capital invested

Capital invested by funds: $19.3B → $20.2B (+$815M)

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

1.15% less ownership

Funds ownership: 91.7%90.55% (-1.1%)

30% less call options, than puts

Call options by funds: $204M | Put options by funds: $291M

Holders
646
Holders Change
+24
Holders Change %
+3.86%
% of All Funds
11.34%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.18%
New
99
Increased
263
Reduced
180
Closed
68
Calls
$204M
Puts
$291M
Net Calls
-$86.4M
Net Calls Change
-$119M
Name Holding Trade Value Shares
Change
Change in
Stake
PAS
276
Park Avenue Securities
New York
$1.54M +$714K +5,213 +81%
PNC Financial Services Group
277
PNC Financial Services Group
Pennsylvania
$1.53M +$1.08M +7,863 +210%
EMPI
278
Elo Mutual Pension Insurance
Finland
$1.51M +$25.3K +185 +2%
MSRPS
279
Maryland State Retirement & Pension System
Maryland
$1.5M +$1.23M +8,969 +374%
VF
280
Virtu Financial
New York
$1.48M -$54.1K -395 -3%
Mackenzie Financial
281
Mackenzie Financial
Ontario, Canada
$1.47M +$485K +3,544 +47%
CCM
282
Canal Capital Management
Virginia
$1.44M +$42.7K +312 +3%
IBT
283
International Biotechnology Trust
United Kingdom
$1.41M
MAM
284
Myriad Asset Management
Hong Kong
$1.37M +$1.42M +10,400 New
AFAS
285
Acorn Financial Advisory Services
Virginia
$1.34M +$52.3K +382 +4%
MLICM
286
Metropolitan Life Insurance Company (MetLife)
New York
$1.29M -$55.8K -408 -4%
GWM
287
Geneos Wealth Management
Colorado
$1.28M
AP
288
AtonRa Partners
Switzerland
$1.27M +$1.32M +9,660 New
Creative Planning
289
Creative Planning
Kansas
$1.27M -$1.21M -8,818 -48%
CIA
290
Capital Impact Advisors
Massachusetts
$1.26M -$8.24M -60,168 -86%
CFGS
291
Concourse Financial Group Securities
Alabama
$1.25M +$164K +1,201 +15%
MWM
292
Midwest Wealth Management
Indiana
$1.24M +$104K +758 +9%
CWP
293
CFM Wealth Partners
Texas
$1.23M
KF
294
Krilogy Financial
Missouri
$1.22M +$69.9K +511 +6%
SMDAM
295
Sumitomo Mitsui DS Asset Management
Japan
$1.19M
SCM
296
Soros Capital Management
New York
$1.15M +$1.2M +8,732 New
DACS
297
Dymon Asia Capital (Singapore)
Singapore
$1.15M +$1.19M +8,713 New
BG
298
Bollard Group
Massachusetts
$1.15M +$1.09M +7,962 +1,086%
CPIG
299
Chicago Partners Investment Group
Illinois
$1.14M -$61.2K -447 -5%
PCTC
300
Perkins Coie Trust Company
Washington
$1.14M

EXAS Hedge Fund Activity: Q1 2021 in Review

646 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Exact Sciences (EXAS) for Q1 2021, worth a combined $20.2B — up 4.2% from $19.3B a quarter earlier.

Buyers outnumbered sellers: 99 funds opened new EXAS positions and 68 closed out — a net gain of 31 holders — while 263 added to existing stakes and 180 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $525M. The largest seller was Wellington Management Group, cutting an estimated $294M.

  • 646 institutional investors held Exact Sciences (EXAS) as of Q1 2021, up from 622 in Q4 2020.
  • Funds reported $20.2B of Exact Sciences stock for Q1 2021, up 4.2% quarter-over-quarter.
  • 99 funds opened new Exact Sciences positions in Q1 2021 and 68 closed out, a net change of +31 holders.
  • The largest Exact Sciences buyer in Q1 2021 was ARK Investment Management, an estimated $525M added.
  • The largest Exact Sciences seller in Q1 2021 was Wellington Management Group, an estimated $294M sold.

Based on aggregated 13F filings for Q1 2021.